ICON Public Limited Company Share Price

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
308.3 USD +2.74% Intraday chart for ICON Public Limited Company +6.97% +8.92%
Sales 2024 * 8.64B 720B Sales 2025 * 9.28B 774B Capitalization 25.49B 2,125B
Net income 2024 * 839M 69.95B Net income 2025 * 1.02B 84.8B EV / Sales 2024 * 3.22 x
Net Debt 2024 * 2.29B 191B Net Debt 2025 * 1.09B 91.07B EV / Sales 2025 * 2.86 x
P/E ratio 2024 *
31.3 x
P/E ratio 2025 *
25.8 x
Employees 41,150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.74%
1 week+6.97%
Current month-8.23%
1 month-6.55%
3 months+15.68%
6 months+28.16%
Current year+8.92%
More quotes
1 week
288.23
Extreme 288.23
318.55
1 month
287.02
Extreme 287.02
338.98
Current year
244.59
Extreme 244.59
344.77
1 year
181.92
Extreme 181.92
344.77
3 years
171.43
Extreme 171.43
344.77
5 years
104.28
Extreme 104.275
344.77
10 years
35.33
Extreme 35.33
344.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/11/01
Director of Finance/CFO 45 01/06/01
Chairman 61 03/05/03
Members of the board TitleAgeSince
Founder 71 01/90/01
Chief Executive Officer 63 01/11/01
Director/Board Member 68 01/21/01
More insiders
Date Price Change Volume
26/24/26 308.3 +2.74% 715,419
25/24/25 300.1 -3.02% 1,196,403
24/24/24 309.4 +0.98% 962,338
23/24/23 306.4 +2.86% 855,919
22/24/22 297.9 +3.37% 778,967

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
308.3 USD
Average target price
354.1 USD
Spread / Average Target
+14.87%
Consensus